Baseline neutrophil-to-lymphocyte ratio (NLR) and early toxicity as prognostic factors in advanced hepatocellular carcinoma patients treated with sorafenib.

• DOI: 10.1200/jco.2015.33.15_suppl.e15159
• Publication Date: 2019-03-07T22:20:33Z
• Authors: Gema Bruixola; Oscar Mauricio Niño; Robert Diaz-Bever...; Encarnacion Reche; Carmen Salvador; Corina Escoin; Dilara Akhoundova; Angel Segura; Alejandra Gimenez; Jorge Aparicio
• Keywords: Univariate analysis

e15159 Background: Sorafenib improves overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC). An elevated baseline NLR has been reported as a possible poor prognostic factor several tumors, including HCC. Early-onset toxicity sorafenib also linked better prognosis. Methods: Retrospective review of sorafenib-treated pts (2008-2014). Baseline NLR, toxicity, early rates (onset 1st 30 days), progression-free (PFS) and OS were assessed. Univariate multivariate analysis factors for was performed. Results: 145 found. characteristics Table 1. Overall G3-4 toxicities: fatigue (19.3%), hand-foot syndrome (HFS) (8.3%) diarrhea (7.6%). Early toxicities (all grades): HFS 42.2% 20.8%. With median follow-up 43 months (mts), PFS 4.15 (CI95% 2,5-5,8) 6.7 mts 4,5-8,8), respectively, 1-year 33%. analysis: Performance status (PS) 0-1, Child-Pugh (C-P) A score, no portal vein thrombosis, prior local therapies, or HFS, early-onset low score (<4) all significant OS. In the study, only PS, C-P retained their value. Conclusions: higher percentage impaired liver function might justify poorer outcomes seen compared to published phase III data. digestive should be evaluated prospectively features, alongside well-established clinical such PS order identify those who could benefit preferentially use sorafenib. Characteristics (n 145) n (%) Median age, yrs (range) 62 (26-82) 0-1 2 135 (93.1) 10 (6,9) Male sex 109 (75,2) CirrhosisNon cirrhosis 118 (81,4) 27 (18,5) B 106 (73.1) 39 (26.9) Barcelona Clinic Liver Cancer staging (BCLC) C 25 (17.2) 120 (82.8) Portal thrombosis 52 (35,9) Distant metastasis 78 (54) Prior therapies 86 (61) <4 95 (69.9)